The latest price target for Moderna (NASDAQ:MRNA) was reported by UBS on February 19, 2025. The analyst firm set a price target for $78.00 expecting MRNA to rise to within 12 months (a possible 145.39% upside). 59 analyst firms have reported ratings in the last year.

The latest analyst rating for Moderna (NASDAQ:MRNA) was provided by UBS, and Moderna maintained their buy rating.

The last upgrade for Moderna Inc happened on November 18, 2024 when HSBC raised their price target to $58. HSBC previously had a hold for Moderna Inc.

The last downgrade for Moderna Inc happened on February 18, 2025 when Barclays changed their price target from $111 to $45 for Moderna Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Moderna, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Moderna was filed on February 19, 2025 so you should expect the next rating to be made available sometime around February 19, 2026.

While ratings are subjective and will change, the latest Moderna (MRNA) rating was a maintained with a price target of $96.00 to $78.00. The current price Moderna (MRNA) is trading at is $31.79, which is out of the analyst’s predicted range.